{"filings":[{"id":99375,"accession_number":"0001437749-26-014996","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo CEO holds Discord town hall; transcript filed as 8-K","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Dennis Calvert participated in a May 5, 2026 town hall on Discord; transcript and investor summary furnished.","No material financial or operational updates disclosed in the filing text or partial transcript excerpts.","Investor summary attached as Exhibit 99.2 is an image; specific figures are not extractable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99374,"accession_number":"0001437749-26-014540","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo CEO to host town hall on Discord May 5; transcript to follow","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Town hall on May 5, 2026 at 1:00 PM PT hosted on BioLargo Shareholder Discord channel.","CEO Dennis Calvert to provide brief company update and Q&A with shareholders.","Meeting will be recorded and transcript filed via 8-K before market open on May 6.","Questions can be pre-submitted in Discord channel #townhall-questions-may-5-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115332,"accession_number":"0001437749-26-009813","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"BioLargo enters $10M equity purchase agreement with Clearthink Capital Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Clearthink commits to buy up to $10M of BioLargo common stock over 36 months under a Strata purchase agreement.","Draws limited to $500K per notice; pricing equals avg of two lowest closing prices in prior 8 trading days; min $25K.","BioLargo issued 500,000 commitment shares to Clearthink as consideration; no cash proceeds from those shares.","Clearthink prohibited from short selling or hedging during term; beneficial ownership capped at 9.99%.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115331,"accession_number":"0001437749-26-007044","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo 2025 revenue falls 56% to $7.8M; net loss widens to $15.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue dropped to $7.8M from $17.8M in 2024 due to termination of largest customer's license.","Net loss of $15.2M vs. $4.3M in prior year; cash balance $3.9M at year end.","Engineering services revenue from third parties grew 98% to $2.0M.","Subsidiary Clyra Medical secured first stocking order for ViaCLYR wound irrigation solution.","PFAS treatment system installed in New Jersey; PFAS breakthrough featured in Chemical Engineering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131747,"accession_number":"0001437749-25-035506","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioLargo issues 624,383 shares to officers for salary; locked until $40M revenue or $300M cap","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two officers converted $99,901 of unpaid salary/expenses into 624,383 shares at $0.16/share.","Shares locked until BioLargo reports consolidated gross revenue ≥$40M, market cap >$300M, or change of control.","Conversion reduces near-term cash outflow and ties officer compensation to long-term company milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131746,"accession_number":"0001437749-25-035203","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo to present investor webcast on Nov 14, 2025 with slides attached","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor webcast scheduled for Nov 14, 2025 at 1:30 PM PT.","Slide deck attached as Exhibit 99.1 (image format) contains business update.","No financial or operational details from slides provided in text form."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131745,"accession_number":"0001437749-25-031354","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo presents at LD Micro Main Event; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company presented slides at LD Micro Main Event on October 20, 2025 in San Diego.","Slides contain company overview and forward-looking statements; no specific financial guidance or operational updates.","Presentation is routine investor relations activity; no changes to business outlook or strategy announced.","No quantitative data, contract wins, or milestone achievements were included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148329,"accession_number":"0001437749-25-029852","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["1.02","2.06","7.01","9.01"],"status":"ready","headline":"BioLargo revokes Pooph license due to $3.8M default; expects substantial impairment of $3.49M note receivable","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pooph owed BioLargo approximately $3.8M in past-due royalties and product invoices; BioLargo revoked license on Sept 24, 2025.","BioLargo expects substantial impairment of its $3.486M note receivable from Pooph on its June 30 balance sheet.","Pooph claims it independently developed a new formula and is terminating the manufacturing agreement, which BioLargo contests as breach.","Pooph's products powered by BioLargo tech reached annual sales over $50M; BioLargo will pursue new odor-control market opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148328,"accession_number":"0001437749-25-027100","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo presents slides at investor conference; no material new details in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Slides were presented at a webcast investor conference on August 15, 2025 at 8:00 AM PT.","Exhibit 99.1 slide deck is incorporated by reference but no specific financial or operational data is provided in the filing body.","No new earnings, guidance, or business updates are disclosed in the 8-K or exhibit text.","Presentation content is furnished under Regulation FD and not deemed filed with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148327,"accession_number":"0001437749-25-023293","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo mid-year update: Clyra distribution deals, Cellinity MOUs, PFAS project; Pooph sales drag","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Clyra Medical secured distribution agreements covering 6,100 hospitals, 6,300 ASCs, 2,200 wound care clinics; raised $3.3M in new capital.","Cellinity battery signed four MOUs with JV partners; each factory >$100M build, $500M annual revenue capacity; targets enterprise value >$2B.","First paid PFAS treatment project in New Jersey underway; AEC removes PFAS below 4 ppt; CEO named to U.S. Dept of Commerce ETTAC.","ONM (Pooph) sales decline led to increased AR, lower cash, downward stock pressure; payback arrangement and new Pooph ads launched.","BLEST engineering revenues grew 152% YoY in Q1 2025; potential multimillion-dollar projects in pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167106,"accession_number":"0001437749-25-021276","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"BioLargo shareholders approve reverse split authorization; board has no immediate plans","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected, including Dennis Calvert, Kenneth Code, Linda Park.","Advisory say-on-pay passed with 54.7% of votes present (103.9M for, 7.9M against).","Ratification of Hacker Johnson & Smith as auditor approved with 99.3% for.","Reverse stock split authorized (51.8% of outstanding shares) but board has no immediate plans to implement.","CEO states reverse split would only be used if needed to meet minimum price for Nasdaq/NYSE uplisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167105,"accession_number":"0001437749-25-017258","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo presents at investor webcast; no financial details in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Slide deck presented at webcast investor conference on May 15, 2025 at 1:30 PM PT.","Filing contains no specific financial or operational updates; exhibit is an image slide deck.","No revenue, earnings, or guidance figures disclosed in the 8-K or text of the exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184471,"accession_number":"0001437749-25-010296","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo reports record 2024 revenues of $17.8M, up 45% YoY; net loss narrows 6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $17.779M, up 45% from 2023; tenth consecutive year of revenue growth.","Net loss $4.347M, down 6% YoY; $3.490M of loss from Clyra Medical operations.","Issued 42% fewer shares in 2024 vs 2023; cash and equivalents $3.548M at Dec 31.","Clyra surgical irrigation products progressing toward national rollout with distribution partner.","Non-cash expenses (stock/options) $2.479M, representing 57% of net loss."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":3269000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201059,"accession_number":"0001437749-24-035426","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo Q3: YTD revenue up 80% to $14.1M; net loss narrows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Year-to-date revenue $14.1M, up 80% YoY; Q3 revenue $4.4M, up 63% YoY.","Net loss narrowed to $1.1M in Q3 (from $1.5M) and $2.6M YTD (from $3.6M).","Current assets $7.4M, cash $3.9M; stockholders' equity $6.0M as of Sept 30, 2024.","CEO says tenth consecutive year of record revenue; expects 2025 to be another record.","Investing in production for national rollout of Clyra Medical Technologies products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":14122000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217077,"accession_number":"0001437749-24-026919","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo files slide deck from May 2024 conference; no new material data","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation from a May 14, 2024 investor webcast is now filed on Form 8-K.","No financial results, guidance, or operational milestones are included in the filing.","Slides contain forward-looking statements and company overview, but no specific new facts.","Company remains listed on OTCQX under ticker BLGO; no business changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236840,"accession_number":"0001437749-24-020750","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"BioLargo shareholders elect all seven directors, approve executive compensation, auditor, and 2024 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected: Dennis Calvert, Kenneth Code, Dennis Marshall, Joseph Provenzano, Jack Strommen, Linda Park, Christina Bray.","Each director received >95M votes for; broker non-votes ~75M.","Advisory vote on exec compensation approved with 96.5% for (94.2M for, 3.5M against, 0.9M abstain).","Ratification of auditor Hacker Johnson & Smith approved with 98.9% for; 2024 Equity Incentive Plan adopted with 98.9% for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236839,"accession_number":"0001437749-24-020181","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo presents slides at annual meeting; no extractable data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Annual stockholder meeting held June 13, 2024; presentation slides furnished.","Slides are not reproduced in text; no specific financial or operational details available.","Filing discloses only that slides were presented; no material new facts reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236838,"accession_number":"0001437749-24-016762","cik":880242,"company_name":"BIOLARGO, INC.","ticker":"BLGO","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioLargo reports record Q1 revenue, positive operating cash flow of $481K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $4.76M, up 28% YoY and 9% QoQ; generated $481K positive operating cash flow.","Net loss $775K including $623K non-cash equity comp; stockholder's equity rose from $4.2M to $5.1M.","Launched water equipment subsidiary for PFAS treatment; appointed Sally Gutierrez, Jeffrey Kightlinger, Larry Dick to board.","EPA finalized PFAS regulations expected to favor BioLargo's treatment technology due to high efficacy and low waste."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":4760000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41393936.45669293,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}